Germany-based Medigene AG has appointed Kirsty Crame to lead clinical research and development for its T cell receptor (TCR) T cell therapies for cancer. Dr Crame joins from Gadeta BV where she led clinical development for that company’s first cellular immunotherapy for cancer. Prior to this, she was a consultant for the biotech and life sciences industry. Dr Crame holds a medical degree from the University of Amsterdam in the Netherlands.
Medigene announced the appointment on 20 March 2022.
Copyright 2023 Evernow Publishing Ltd